{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,12]],"date-time":"2025-11-12T14:07:05Z","timestamp":1762956425735,"version":"3.41.2"},"reference-count":13,"publisher":"Oxford University Press (OUP)","issue":"10","license":[{"start":{"date-parts":[[2020,9,23]],"date-time":"2020-09-23T00:00:00Z","timestamp":1600819200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2020,10,1]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Babesiosis with high-grade parasitemia is life-threatening, especially in asplenic hosts. We report an asplenic patient with parasitemia &amp;gt;50% who was successfully treated with prompt red blood cell apheresis and triple therapy with clindamycin\u2005+\u2005azithromycin\u2005+\u2005atovaquone. This regimen may be an alternative to poorly tolerated clindamycin\u2005+\u2005quinine in severe cases.<\/jats:p>","DOI":"10.1093\/ofid\/ofaa448","type":"journal-article","created":{"date-parts":[[2020,9,23]],"date-time":"2020-09-23T12:07:55Z","timestamp":1600862875000},"source":"Crossref","is-referenced-by-count":5,"title":["Case Report: Overwhelming Babesia Parasitemia Successfully Treated Promptly With RBC Apheresis and Triple Therapy With Clindamycin, Azithromycin, and Atovaquone"],"prefix":"10.1093","volume":"7","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5300-0571","authenticated-orcid":false,"given":"Yijia","family":"Li","sequence":"first","affiliation":[{"name":"Infectious Diseases Unit, Massachusetts General Hospital, Boston, Massachusetts, USA"},{"name":"Division of Infectious Diseases Brigham and Women\u2019s Hospital, Boston, Massachusetts, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Susan","family":"Stanley","sequence":"additional","affiliation":[{"name":"Infectious Diseases Unit, Massachusetts General Hospital, Boston, Massachusetts, USA"},{"name":"Division of Infectious Diseases Brigham and Women\u2019s Hospital, Boston, Massachusetts, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Julian A","family":"Villalba","sequence":"additional","affiliation":[{"name":"Department of Pathology, Massachusetts General Hospital, Boston, Massachusetts, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sandra","family":"Nelson","sequence":"additional","affiliation":[{"name":"Infectious Diseases Unit, Massachusetts General Hospital, Boston, Massachusetts, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jeffrey","family":"Gelfand","sequence":"additional","affiliation":[{"name":"Infectious Diseases Unit, Massachusetts General Hospital, Boston, Massachusetts, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2020,9,23]]},"reference":[{"author":"Centers for Disease Control and Prevention","key":"2020102409204199800_CIT0001","article-title":"Babesiosis: Number and incidence of reported cases of babesiosis, by state and year, 2011\u20132017"},{"key":"2020102409204199800_CIT0002","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1086\/508667","article-title":"The clinical assessment, treatment, and prevention of lyme disease, human granulocytic anaplasmosis, and babesiosis: clinical practice guidelines by the Infectious Diseases Society of America","volume":"43","author":"Wormser","year":"2006","journal-title":"Clin Infect Dis"},{"key":"2020102409204199800_CIT0003","doi-asserted-by":"crossref","first-page":"601","DOI":"10.7326\/0003-4819-96-5-601","article-title":"Successful chemotherapy of transfusion babesiosis","volume":"96","author":"Wittner","year":"1982","journal-title":"Ann Intern Med"},{"key":"2020102409204199800_CIT0004","doi-asserted-by":"crossref","first-page":"1454","DOI":"10.1056\/NEJM200011163432004","article-title":"Atovaquone and azithromycin for the treatment of babesiosis","volume":"343","author":"Krause","year":"2000","journal-title":"N Engl J Med"},{"key":"2020102409204199800_CIT0005","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1016\/j.transci.2019.07.010","article-title":"Repeat exchange transfusion for treatment of severe babesiosis","volume":"58","author":"Radcliffe","year":"2019","journal-title":"Transfus Apher Sci"},{"key":"2020102409204199800_CIT0006","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1002\/jca.21492","article-title":"Babesia parasitemia rebound after red blood cell exchange","volume":"32","author":"Alquist","year":"2017","journal-title":"J Clin Apheresis"},{"key":"2020102409204199800_CIT0007","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1186\/s12941-017-0198-9","article-title":"Babesiosis in Long Island: review of 62 cases focusing on treatment with azithromycin and atovaquone","volume":"16","author":"Kletsova","year":"2017","journal-title":"Ann Clin Microbiol Antimicrob"},{"volume-title":"Qualaquin","author":"FDA","key":"2020102409204199800_CIT0008"},{"key":"2020102409204199800_CIT0009","doi-asserted-by":"crossref","first-page":"556","DOI":"10.7326\/0003-4819-97-4-556","article-title":"Therapy of experimental babesiosis","volume":"97","author":"Rowin","year":"1982","journal-title":"Ann Intern Med"},{"key":"2020102409204199800_CIT0010","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1093\/infdis\/168.5.1289","article-title":"Efficacy of azithromycin for treating Babesia microti infection in the hamster model","volume":"168","author":"Weiss","year":"1993","journal-title":"J Infect Dis"},{"key":"2020102409204199800_CIT0011","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1093\/infdis\/jiaa195","article-title":"Clofazimine, a promising drug for the treatment of Babesia microti infection in severely immunocompromised hosts","volume":"222","author":"Tuvshintulga","year":"2020","journal-title":"J Infect Dis"},{"key":"2020102409204199800_CIT0012","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1186\/s13071-020-04235-7","article-title":"Activities of artesunate-based combinations and tafenoquine against Babesia bovis in vitro and Babesia microti in vivo","volume":"13","author":"Carvalho","year":"2020","journal-title":"Parasit Vectors"},{"key":"2020102409204199800_CIT0013","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1093\/infdis\/jiz119","article-title":"Could the drug tafenoquine revolutionize treatment of Babesia microti infection?","volume":"220","author":"Mordue","year":"2019","journal-title":"J Infect Dis"}],"container-title":["Open Forum Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/ofid\/advance-article-pdf\/doi\/10.1093\/ofid\/ofaa448\/33783694\/ofaa448.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/ofid\/article-pdf\/7\/10\/ofaa448\/34006075\/ofaa448.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/ofid\/article-pdf\/7\/10\/ofaa448\/34006075\/ofaa448.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,4,3]],"date-time":"2021-04-03T17:36:00Z","timestamp":1617471360000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ofid\/article\/doi\/10.1093\/ofid\/ofaa448\/5910422"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,9,23]]},"references-count":13,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2020,10,1]]}},"URL":"https:\/\/doi.org\/10.1093\/ofid\/ofaa448","relation":{},"ISSN":["2328-8957"],"issn-type":[{"type":"electronic","value":"2328-8957"}],"subject":[],"published-other":{"date-parts":[[2020,10]]},"published":{"date-parts":[[2020,9,23]]},"article-number":"ofaa448"}}